Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 51, 2016, Pages E8277-E8285

  Lévy, Romain ^a,b   Okada, Satoshi ^b,c   Béziat, Vivien ^a   Moriya, Kunihiko ^a   Liu, Caini ^d   Chai, Louis Yi Ann ^a,t   Migaud, Mélanie ^a   Hauck, Fabian ^e   Al Ali, Amein ^f   Cyrus, Cyril ^f   Vatte, Chittibabu ^f   Patiroglu, Turkan ^g   Unal, Ekrem ^g   Ferneiny, Marie ^h   Hyakuna, Nobuyuki ⁱ   Nepesov, Serdar ^j   Oleastro, Matias ^k   Ikinciogullari, Aydan ^l   Dogu, Figen ^l   Asano, Takaki ^c   Ohara, Osamu ^m   Yun, Ling ^a   Della Mina, Erika ^a   Bronnimann, Didier ^a   Itan, Yuval ^b   Gothe, Florian ^e   Bustamante, Jacinta ^a,b,h   Boisson Dupuis, Stéphanie ^a,b   Tahuil, Natalia ⁿ   Aytekin, Caner ^o   Salhi, Aicha ^p   Al Muhsens, Saleh ^q   Kobayashi, Masao ^c   Toubiana, Julie ^h   Abel, Laurent ^a,b   Li, Xiaoxia ^d   Camcioglu, Yildiz ^j   Celmeli, Fatih ^r   Klein, Christoph ^e   Alkhater, Suzan A ^f   Casanova, Jean Laurent ^a,b,h,s   Puel, Anne ^a,b   more..

^a IMAGINE INSTITUTE   (France)

^b ROCKEFELLER UNIVERSITY   (United States)

^c HIROSHIMA UNIVERSITY   (Japan)

^d LERNER RESEARCH INSTITUTE   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^g ERCIYES UNIVERSITY   (Turkey)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ UNIVERSITY OF THE RYUKYUS   (Japan)

^j ISTANBUL UNIVERSITY   (Turkey)

^k Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^l ANKARA UNIVERSITY   (Turkey)

^m KAZUSA DNA RESEARCH INSTITUTE   (Japan)

ⁿ Hospital del Nino Jesus Argentina   (Argentina)

^o DR SAMI ULUS MATERNITY AND CHILDREN S HEALTH AND DISEASES TRAINING AND RESEARCH HOSPITAL   (Turkey)

^p Benyoucef Benkhedda   (Algeria)

^q KING SAUD UNIVERSITY   (Saudi Arabia)

^r Antalya Education and Research Hospital   (Turkey)

^s HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^t NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

more..

Author keywords

Candidiasis; Genetics; Immunodeficiency

Indexed keywords

BETA DEFENSIN 2; GAMMA INTERFERON; HETERODIMER; HOMODIMER; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 6; IL17A PROTEIN, HUMAN; IL17F PROTEIN, HUMAN; IL17RA PROTEIN, HUMAN; IL25 PROTEIN, HUMAN;

ABSCESS; ADOLESCENT; ADULT; ALLELE; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; FIBROBLAST; FOLLICULITIS; FURUNCULOSIS; GENE EXPRESSION; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFANT; INTERLEUKIN 17A RECEPTOR DEFICIENCY; LEUKOCYTE; LOBAR PNEUMONIA; LUNG TUBERCULOSIS; LYMPHOCYTE SUBPOPULATION; MALE; MISSENSE MUTATION; MONOCYTE; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; OTITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PREMATURE STOP CODON; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PUSTULE; RECURRENT INFECTION; SANGER SEQUENCING; SCHOOL CHILD; SINUSITIS; SKIN FIBROBLAST; STOP CODON; TUBERCULOUS MENINGITIS; WESTERN BLOTTING; YOUNG ADULT; CANDIDA; CANDIDIASIS; CELL MEMBRANE; CYTOLOGY; DEFICIENCY; FAMILY HEALTH; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HEK293 CELL LINE; HOMOZYGOTE; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MICROBIOLOGY; MUTATION; NEWBORN; OPEN READING FRAME; PEDIGREE; RECESSIVE GENE; SKIN; T LYMPHOCYTE;

ALLELES; BACTERIAL INFECTIONS; CANDIDA; CANDIDIASIS; CELL MEMBRANE; CHILD; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; FIBROBLASTS; GENES, RECESSIVE; GENOME-WIDE ASSOCIATION STUDY; HEK293 CELLS; HOMOZYGOTE; HUMANS; IMMUNOPHENOTYPING; INFANT; INFANT, NEWBORN; INTERLEUKIN-17; MALE; MUTATION; MYCOSES; OPEN READING FRAMES; PEDIGREE; RECEPTORS, INTERLEUKIN-17; SKIN; T-LYMPHOCYTES;

EID: 85006873332     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1618300114     Document Type: Article

References (95)

1. Puel A, et al. (2012) Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 12(6):616-622.
2. Chandesris M-O, et al. (2012) Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: Molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) 91(4):e1-e19.
3. Kisand K, Peterson P (2015) Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Clin Immunol 35(5):463-478.
4. Wells RS, Higgs JM, Macdonald A, Valdimarsson H, Holt PJ (1972) Familial chronic muco-cutaneous candidiasis. J Med Genet 9(3):302-310.
5. Chilgren RA, Quie PG, Meuwissen HJ, Hong R (1967) Chronic mucocutaneous candidiasis, deficiency of delayed hypersensitivity, and selective local antibody defect. Lancet 2(7518):688-693.
6. Puel A, et al. (2010) Inborn errors of mucocutaneous immunity to Candida albicans in humans: A role for IL-17 cytokines? Curr Opin Immunol 22(4):467-474.
7. Casanova J-L (2015) Human genetic basis of interindividual variability in the course of infection. Proc Natl Acad Sci USA 112(51):E7118-E7127.
8. Casanova J-L (2015) Severe infectious diseases of childhood as monogenic inborn errors of immunity. Proc Natl Acad Sci USA 112(51):E7128-E7137.
9. Puel A, et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332(6025):65-68.
10. Ling Y, et al. (2015) Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med 212(5):619-631.
11. Boisson B, et al. (2013) An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39(4):676-686.
12. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9(8):556-567.
13. Aldave JC, et al. (2013) A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation. J Clin Immunol 33(8):1273-1275.
14. Altman MC, et al. (2014) A young boy with a novel, autosomal-dominant signal transducer and activator of transcription 1 (STAT1) hypermorphic mutation presenting with pneumocystis Jirovecii pneumonia (PJP), chronic mucocutaneous candidiasis (CMC), and combined immunodeficiency. J Allergy Clin Immunol 133(2 Suppl):AB250.
15. Baer Ellington AE, Shih JA (2014) Sporadic case of chronic mucocutaneous candidiasis (CMC) due to a gain-of-function mutation in STAT1 in a 13 year old female. J Allergy Clin Immunol 133(2 Suppl):AB250.
16. Bina SM, et al. (2014) Variable presentations of gain of function STAT1 mutations within a single institution with features beyond chronic mucocutaneous candidiasis. J Allergy Clin Immunol 135(2 Suppl):AB186.
17. Depner M, et al. (2016) The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol 36(1):73-84.
18. Dhalla F, et al. (2016) Chronic mucocutaneous candidiasis: Characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility. Clin Exp Immunol 184(2):216-227.
19. Dotta L, et al. (2016) Clinical heterogeneity of dominant chronic mucocutaneous candidiasis disease: Presenting as treatment-resistant candidiasis and chronic lung disease. Clin Immunol 164:1-9.
20. Frans G, et al. (2014) Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): Chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding. J Allergy Clin Immunol 134(5):1209-13.e6.
21. Giardino G, et al. (2016) Novel STAT1 gain-of-function mutation and suppurative infections. Pediatr Allergy Immunol 27(2):220-223.
22. Higgins E, et al. (2015) Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135(2):551-553.
23. Hori T, et al. (2012) Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism. J Clin Immunol 32(6):1213-1220.
24. Kataoka S, et al. (2016) Extrapulmonary tuberculosis mimicking Mendelian susceptibility to mycobacterial disease in a patient with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 137(2):619-622.e1.
25. Kilic SS, Puel A, Casanova J-L (2015) Orf Infection in a patient with Stat1 gain-of-function. J Clin Immunol 35(1):80-83.
26. Kumar N, et al. (2014) Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J Allergy Clin Immunol 134(1):236-239.
27. Lee PPW, et al. (2014) Penicillium marneffei infection and impaired IFN-γ immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations. J Allergy Clin Immunol 133(3):894-6.e5.
28. Liu L, et al. (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208(8):1635-1648.
29. Martinez-Martinez L, et al. (2015) A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis. Mol Immunol 68(2 Pt C):597-605.
30. Mekki N, et al. (2014) IL-17 T cells' defective differentiation in vitro despite normal range ex vivo in chronic mucocutaneous candidiasis due to STAT1 mutation. J Invest Dermatol 134(4):1155-1157.
31. Mizoguchi Y, et al. (2014) Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis. J Leukoc Biol 95(4):667-676.
32. Mössner R, et al. (2016) Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis 62(7):951-953.
33. Romberg N, et al. (2013) Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J Allergy Clin Immunol 131(6):1691-1693.
34. Ruda Wessell KM, et al. (2015) A young adult male with chronic mucocutaneous candidiasis (CMC) with signal transduction and activator of transcription 1 (STAT 1) mutation and progressive multifocal leukoencephalopathy (PML). J Allergy Clin Immunol 135(2 Suppl):AB186.
35. Al Rushood M, et al. (2013) Autosomal dominant cases of chronic mucocutaneous candidiasis segregates with mutations of signal transducer and activator of transcription 1, but not of Toll-like receptor 3. J Pediatr 163(1):277-279.
36. Nielsen J, et al. (2015) A STAT1-gain-of-function mutation causing Th17 deficiency with chronic mucocutaneous candidiasis, psoriasiform hyperkeratosis and dermatophytosis. BMJ Case Rep 2015:bcr2015211372.
37. Salim N, Leiding J (2014) Fungal granuloma and chronic mucocutaneous candidiasis due to autosomal dominant gain of function STAT1 mutation. J Allergy Clin Immunol 133(2 Suppl):AB251.
38. Sampaio EP, et al. (2013) Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol 131(6):1624-1634.
39. Sharfe N, et al. (2014) Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. J Allergy Clin Immunol 133(3):807-817.
40. Smeekens SP, et al. (2011) STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS One 6(12):e29248.
41. Soltész B, et al. (2013) New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet 50(9):567-578.
42. Takezaki S, et al. (2012) Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 189(3):1521-1526.
43. Tanimura M, et al. (2015) Recurrent inflammatory aortic aneurysms in chronic mucocutaneous candidiasis with a gain-of-function STAT1 mutation. Int J Cardiol 196:88-90.
44. Tóth B, et al. (2012) Herpes in STAT1 gain-of-function mutation. Lancet 379(9835):2500
45. erratum Tóth B, et al. (2012) Herpes in STAT1 gain-of-function mutation. Lancet 380(9844):806.
46. Uzel G, et al. (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131(6):1611-1623.
47. van de Veerdonk FL, et al. (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365(1):54-61.
48. Wang X, et al. (2013) Exome sequencing reveals a signal transducer and activator of transcription 1 (STAT1) mutation in a child with recalcitrant cutaneous fusariosis. J Allergy Clin Immunol 131(4):1242-1243.
49. Wildbaum G, et al. (2013) Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol 132(3):761-764.
50. Yamazaki Y, et al. (2014) Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: Impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol 193(10):4880-4887.
51. Zerbe CS, et al. (2016) Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature. Clin Infect Dis 62(8):986-994.
52. Toubiana J, et al.; International STAT1 Gain-of-Function Study Group (2016) Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127(25):3154-3164.
53. Zheng J, et al. (2015) Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). Eur J Immunol 45(10):2834-2846.
54. Okada S, et al. (2015) IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 349(6248):606-613.
55. de Beaucoudrey L, et al. (2008) Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 205(7):1543-1550.
56. Ma CS, et al. (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205(7):1551-1557.
57. Milner JD, et al. (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452(7188):773-776.
58. Renner ED, et al. (2008) Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 122(1):181-187.
59. Kisand K, et al. (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207(2):299-308.
60. Puel A, et al. (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207(2):291-297.
61. Fellmann F, et al. (2016) IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol 137(4):1189-1196.e1-2.
62. Onishi RM, et al. (2010) SEF/IL-17R (SEFIR) is not enough: An extended SEFIR domain is required for il-17RA-mediated signal transduction. J Biol Chem 285(43):32751-32759.
63. Maitra A, et al. (2007) Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci USA 104(18):7506-7511.
64. Scott EM, et al.; Greater Middle East Variome Consortium (2016) Characterization of Greater Middle Eastern genetic variation for enhanced disease gene discovery. Nat Genet 48(9):1071-1076.
65. Itan Y, et al. (2016) The mutation significance cutoff: Gene-level thresholds for variant predictions. Nat Methods 13(2):109-110.
66. Kircher M, et al. (2014) A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46(3):310-315.
67. Allende LM, et al. (2001) A point mutation in a domain of gamma interferon receptor 1 provokes severe immunodeficiency. Clin Diagn Lab Immunol 8(1):133-137.
68. Jouanguy E, et al. (2000) In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. J Clin Invest 105(10):1429-1436.
69. Camcioglu Y, et al. (2004) HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J Pediatr 144(4):519-523.
70. Dorman SE, et al. (2004) Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364(9451):2113-2121.
71. Vogt G, et al. (2005) Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 37(7):692-700.
72. Vogt G, et al. (2008) Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. J Exp Med 205(8):1729-1737.
73. Fieschi C, et al. (2004) A novel form of complete IL-12/IL-23 receptor beta1 deficiency with cell surface-expressed nonfunctional receptors. Blood 104(7):2095-2101.
74. Fieschi C, et al. (2003) Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: Medical and immunological implications. J Exp Med 197(4):527-535.
75. Mao H, et al. (2012) Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. Genes Immun 13(5):437-442.
76. Begue B, et al. (2011) Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 106(8):1544-1555.
77. McAleer JP, Kolls JK (2014) Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 260(1):129-144.
78. Ye P, et al. (2001) Requirment of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194(4):519-527.
79. Minegishi Y, et al. (2009) Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome. J Exp Med 206(6):1291-1301.
80. Shen F, Gaffen SL (2008) Structure-function relationships in the IL-17 receptor: Implications for signal transduction and therapy. Cytokine 41(2):92-104.
81. Gaffen SL, Jain R, Garg AV, Cua DJ (2014) The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing. Nat Rev Immunol 14(9):585-600.
82. Rickel EA, et al. (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181(6):4299-4310.
83. Song X, et al. (2011) IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol 12(12):1151-1158.
84. Ramirez-Carrozzi V, et al. (2011) IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol 12(12):1159-1166.
85. Qian Y, et al. (2007) The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 8(3):247-256.
86. Chang SH, Park H, Dong C (2006) Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 281(47):35603-35607.
87. Swaidani S, et al. (2009) The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J Immunol 182(3):1631-1640.
88. Ho AW, et al. (2010) IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J Immunol 185(2):1063-1070.
89. Chang SH, et al. (2011) Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity 35(4):611-621.
90. Angkasekwinai P, et al. (2007) Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 204(7):1509-1517.
91. Fort MM, et al. (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15(6):985-995.
92. Angkasekwinai P, et al. (2013) Interleukin-25 (IL-25) promotes efficient protective immunity against Trichinella spiralis infection by enhancing the antigen-specific IL-9 response. Infect Immun 81(10):3731-3741.
93. Zhao A, et al. (2010) Critical role of IL-25 in nematode infection-induced alterations in intestinal function. J Immunol 185(11):6921-6929.
94. Fallon PG, et al. (2006) Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J Exp Med 203(4):1105-1116.
95. Conti HR, et al. (2015) Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. PLoS One 10(4):e0122807.